Journal: Cells

Article Title: Antiangiogenic Action of JZL184 on Endothelial Cells via Inhibition of VEGF Expression in Hypoxic Lung Cancer Cells.

doi: 10.3390/cells12192332

Figure Lengend Snippet: Figure 12. Concentration-dependent effect of rVEGF-165 on VEGFR2 phosphorylation at residue 1175 (A), effect of JZL184 on rVEGF-induced VEGFR2 phosphorylation (B) and viability (C) of HUVECs. In (A), HUVECs were stimulated with rVEGF at the indicated concentrations for 5 min. In (B), HUVECs were pre-incubated with JZL184 at selected concentrations for 6 h, followed by stimulation with recombinant VEGF-165 (10 ng/mL) for 5 min. In (C), viability was determined using the WST-1 assay after 48 h of co-incubation of rVEGF-165 and JZL184. Western blot images are representative of each experiment. All percentages shown refer to vehicle-treated HUVECs set at 100%. Data are mean ± SEM of n = 4 (B) or n = 7–8 (C). In (A), a representative blot of a total of 2 experiments performed is shown. **** p ≤0.0001 vs. vehicle-treated HUVECs; # p ≤0.05 vs. rVEGF-165-stimulated HUVECs; one-way ANOVA with Bonferroni´s post hoc test (C). In (B), a significant effect of JZL184 was not identified as determined by one-way ANOVA with Dunnett´s post hoc test.

Article Snippet: Recombinant human VEGF-165 (rVEGF, #HZ-1038) and recombinant human serum albumin (rHSA, #HZ-3001) were purchased from Proteintech (PlaneggMartinsried, Germany).

Techniques: Concentration Assay, Phospho-proteomics, Residue, Incubation, Recombinant, WST-1 Assay, Western Blot